Talking Deal Prices with Steve Gelsi: Biomet's 1.4x return for sponsors trumps IPO; newspapers as contrarian play
The buyout of Biomet Group by strategic competitor Zimmer Holdings Inc, valued at $13.35 billion, has trumped plans by the orthopedic medical device firm’s sponsors to take the firm public. The deal is in line to deliver healthy gains, despite the purchase price paid for Biomet at a time of frothy transactions for private equity consortia.
29 April 2014•3 mins read
